一例COVID-19肺炎患者肺部的177Lu-DOTATATE摄取
一例76岁女性十二指肠神经内分泌肿瘤肝骨转移患者接受177Lu-DOTATATE肽受体放射性核素治疗,治疗后4天SPECT/CT显示双肺多灶性磨玻璃影摄取177Lu-DOTATATE,因治疗前7天感染新冠病毒,考虑为COVID-19肺炎所致;第二次治疗后2个月肺部磨玻璃影缩小、摄取减低。
要点
- 177Lu-DOTATATE可能在COVID-19肺炎活动期被肺部病灶摄取。
- 治疗后4天SPECT/CT示双肺多灶性磨玻璃影伴177Lu-DOTATATE摄取。
- 第二次治疗后2个月肺部磨玻璃影缩小、摄取减低。
核心结论
- 177Lu-DOTATATE可能在COVID-19肺炎活动期被摄取。
研究设计与样本
- 一例76岁女性十二指肠神经内分泌肿瘤肝骨转移患者的病例报告,接受177Lu-DOTATATE肽受体放射性核素治疗。
主要发现
- 治疗后4天SPECT/CT显示双肺多灶性磨玻璃影摄取177Lu-DOTATATE。
- 患者治疗前7天感染新冠病毒,该摄取被认为由COVID-19肺炎所致。
- 第二次治疗后2个月肺部磨玻璃影缩小、摄取减低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 76-year-old woman with liver and bone metastasis of a duodenal neuroendocrine tumor received peptide receptor radionuclide therapy with 177 Lu-DOTATATE. Scintigraphy with SPECT/CT performed 4 days after the treatment demonstrated 177 Lu-DOTATATE uptake as multifocal ground glass opacities in the bilateral lungs. This uptake was considered to be due to COVID-19 pneumonia because the patient was infected with the virus 7 days prior to the treatment. The lung opacities became smaller, showing a decreased uptake, 2 months later, after the second treatment. 177 Lu-DOTATATE may be taken up during the active phase of COVID-19 pneumonia.
引用
- Matsushita T, Otomi Y, Okada N, et al. 177 Lu-DOTATATE Uptake in the Lungs of a Patient With COVID-19 Pneumonia. Clin Nucl Med. 2024. PMID: 38968595. doi:10.1097/RLU.0000000000005324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。